- subject with active hcv, hbv or hiv infection. - subject is albumin-intolerant. - subject with life expectancy less than 4 weeks. - subject participated in other investigational vaccine therapies within the past 60 days. - subject with positive pregnancy test result. - researchers consider unsuitable.

- subject with active hcv, hbv or hiv infection. - subject is albumin-intolerant. - subject with life expectancy less than 4 weeks. - subject participated in other investigational vaccine therapies within the past 60 days. - subject with positive pregnancy test result. - researchers consider unsuitable.